CPU86017: A novel class III antiarrhythmic agent with multiple actions at ion channels

Cardiovascular Drug Reviews

Volumn 24, Issue 2, 2006, Pages 101-115

  Dai, De Zai ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Antiarrhythmics; Calcium; Calstabin; Channelopathy; CPU86017; ICaL currents; IKR currents; IKS currents; Ion channels; Myocardium; Patch clamp; Phospholamban; Ryanodine receptor; SERCA2a

Indexed keywords

4 [3 (4 BENZYL 1 PIPERIDINYL)PROPIONYL] 2,3,4,5 TETRAHYDRO 7 METHOXY 1,4 BENZOTHIAZEPINE; 4 CHLOROBENZYL TETRAHYDROBERBERINE; AMIODARONE; ANTIARRHYTHMIC AGENT; BERBERINE; BERBERINE DERIVATIVE; CALCIUM CHANNEL L TYPE; CPU 86017; DOFETILIDE; ION CHANNEL; ISOPRENALINE; LIDOCAINE; OUABAIN; POTASSIUM CHANNEL; PROPAFENONE; RYANODINE RECEPTOR 2; UNCLASSIFIED DRUG; 4 CHLOROBENZYLTETRAHYDROBERBERINE; 4-CHLOROBENZYLTETRAHYDROBERBERINE; DRUG DERIVATIVE;

ANTIARRHYTHMIC ACTIVITY; ANTIOXIDANT ACTIVITY; CALCIUM CURRENT; CORONARY ARTERY LIGATION; DOG; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG POTENCY; DRUG TISSUE LEVEL; GENE MUTATION; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; HEART VENTRICLE ARRHYTHMIA; IC 50; LD 50; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QT PROLONGATION; RABBIT; REVIEW; SINUS NODE; SUDDEN DEATH; SYSTEMATIC REVIEW; TORSADE DES POINTES; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CLASSIFICATION; DRUG ANTAGONISM; HEART VENTRICLE FIBRILLATION; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; BERBERINE; DEATH, SUDDEN, CARDIAC; HUMANS; ION CHANNELS; MOLECULAR STRUCTURE; VENTRICULAR FIBRILLATION;

EID: 33847652782     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2006.00101.x     Document Type: Review

References (46)

1. Cardiac Arrhythmia Suppression Trial Investigations. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmias suppression after myocardial infarction. N Engl J Med 1989 321 : 406 412.
2. Chow DJ, Collb M, Bimie D. Brugada syndrome precipitated by a tricyclic anti-depressant. Heart 2005 91 (5 651.
3. Colastsky TJ. Antiarrhythmic drugs: Where are we going Pharm News 1995 2 : 17 23.
4. Cui YJ, Yang P, Dai DZ, Gao L, Xiao DW, Wang YQ. CPU 86017 Suppresses tachyarrhythmias induced by ouabain and myocardial infarction: Concentrations in plasma and different areas of the heart in dogs. Drug Dev Res 2003 58 : 131 137.
5. Dai DZ. Vulnerable substrate and multiple ion channel disorder in a diseased heart will be new targets for antiarrhythmic therapy. Acta Pharmacol Sinica 2000 21 : 289 295.
6. Dai DZ. Ion channelopathies which induce cardiac arrhythmias novel target of drug development. J Chin Pharmacol Univ 2002 33 : 173 177.
7. Dai DZ. Ion channelopathies relating to cardiac arrhythmias in cardiomyopathy respond to drug interventions. Drug Dev Res 2006 66 : 216 (xAbstract).
8. Dai DZ. Two patterns of ion channelopathy in the myocardium: Perspectives for development of anti-arrhythmic agents. Curr Opin Invest Drugs 2005 6 (3 289 297.
9. Dai DZ. The anti-arrhythmic activity of protoberberines in relation to blockade of ion channels. Ion Channel Modulators 1997 2 : 383 390.
10. Dai DZ, An LF, Wang YQ, et al. CPU 86017 suppression of arrhythmias induced by ischemia/reperfusion, ouabain, aconitine, and elevxation of ventricular fibrillatory threshold. Drug Dev Res 1996 39 : 184 190.
11. Dai DZ, Hu HJ, Zhao J, et al. Blockade of L-type calcium channel in myocardium and calcium-induced contractions of vascular smooth muscle by CPU 86017. Acta Pharmacol Sinica 2004 25 (4 4164 4123.
12. Dai, DZ., Yu F. Ion channelopathy and hyperphosphorylation contributing to cardiac arrhythmias. Acta Pharmacol Sinica 2005 26 : 918 925.
13. Dai DZ, Yu F, Li HT, et al. Blockade on sodium, potassium, and calcium channels by a new antiarrhythmic agent CPU86017. Drug Dev Res 1996 39 : 138 146.
14. Dai DZ, Zhnag GQ, Yang P, Ma YP. Two pattern of ion channelopathies relating to arrhythmias and direct and indirect blockade of ion channels by antiarrhythmic agents. Drug Dev Res 2003 58 : 42 50.
15. Dumaine R, Antzelevitch C. Molecular mechanisms underlying the long QT syndrome. Curr Opin Cardiol 2002 17 : 36 42.
16. Fan JS, Dai DZ, Wu M, Sheng LS. A HPLC assay of plasma levels and pharmacokinetics following intravenous single bolus of a novel antiarrhythmic agent 86017 in rabbits. Bull New Drug Res Found 1991 1 : 94 98.
17. Gollob MH. Genetic profiling as a marker for risk of sudden cardiac death. Curr Opin Cardiol 2006 21 (1 42 46.
18. Guerra PG, Talajic M, Roy D, Dubuc M, Thibault B, Nattel S. Is there a future for antiarrhythmic drug therapy Drugs 1998 56 : 767 781.
19. Hao JM, Dai DZ, Yu F. The oxidative stress enhancing effects by L-thyroxin and the antioxidant effects of CPU86017, a derivative of tetrahydroberberine. Prog Pharmacol Sci 1995 29 : 417 421.
20. Khan HH, Dai DZ, Xiao DW, Lin S, Wang ZZ. Plasma CPU-86017 concentrations regarding suppression of ouabain-induced cardiac arrhythmias and decrease of heart rate in guinea pigs. Acta Pharmacol Sinica 2000 21 (11 1039 1042.
21. Kohno M, Yano M, Kobayashi S, et al. Anew cardioprotective agent, JTV519, improves defective channel gating of ryanodine receptor in heart failure. Am J Physiol Heart Circ Physiol 2003 284 (3 H1035 1042.
22. Li HT, Dai DZ, Wu CH, Zhou PA, Hao XM. Effect of chlorobenzyltetraberberine on potassium channels in isolated guinea pig ventricular myocytes. J Chin Pharmacol Univ 1998 29 : 57 60.
23. Li HT, Lin S, Dai DZ. Effects of CPU86017 (p.o.) on arrhythmias in dogs with coronary ligation. Chin J Pract Med 2004 4 : 2134 2136.
24. Ma YP, Hao XM, Zhang GQ, Zhou PA, Wu CH, Dai DZ. Blocking effect of CPU86017 on slowly activated rectifier potassium currents in single ventricular myocytes of guinea pigs. J Chin Pharmacol Univ 2000 31 : 121 125.
25. Nabauer M, Kaab S. Potassium channel down-regulation in heart failure. Cardiovasc Res 1998 37 : 324 334.
26. Olson EN. A decade of discoveries in cardiac biology. Nat Med 2004 10 : 467 474.
27. Roden DM, Balser JR, George, AL Jr. Anderson, ME. Cardiac ion channels. Ann Rev Physiol 2002 64 : 431 475.
28. Rubart M, Zipes DP. Mechanisms of sudden cardiac death. J Clin Invest 2005 115 : 2305 2315.
29. Schwartz PJ. Management of long QT syndrome. Nat Clin Pract Cardiovasc Med 2005 2 (7 346 351.
30. Splawski I, Timothy KW, Tateyama M, et al. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmias. Science 2002 297 (5585 1333 1337.
31. Sumitomo N, Harada K, Nagashima M, et al. Catecholaminergic polymorphic ventricular tachycardia: Electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. Heart 2003 89 (1 66 70.
32. Tomaselli GT, Zipes DP. What causes sudden death in heart failure Circ Res 2004 95 : 754 763.
33. Van Gelder IC, Brugemann J, Crijns HJ. Current treatment recommendations in antiarrhythmic therapy. Drugs 1998 55 : 331 346.
34. Vest JA, Wehrens XH, Reiken SR, et al. Defective cardiac ryanodine receptor regulation during atrial fibrillation. Circulation 2005 111 (16 2025 2032.
35. Wang GJ, Gao L, Yang P, Sun JG, Fu JH, Zhang ZQ. Pharmacokinetics and pharmacodynamics of 7-(4-chlorbenzyl)-7,8,13,13a-tetrahydroberberine chloride in dogs. Chin J Pharmacol Toxicol 2000 14 : 72 75.
36. Wang HL, Dai DZ, Gao F, Zhang YP, Lu F. Dispersion of ventricular mRNA of RyR2, and SERCA associated with arrhythmogenesis in rats. Acta Pharmacol Sinica 2004 25 : 738 743.
37. Wang HL, Li ZB, Dai DZ. Effects of CPU86017 on L-type calcium current in single hypertrophic ventricular myocytes. J Chin Pharmacol Univ 2004 35 : 344 348.
38. Wang RF, Xu GY, Hua WY, Peng SX. Synthesis and antiarrhythmic activity of some tetrahydroberberine quaternary ammonium compounds. Chin J Med Chem 1996 6 : 243 248.
39. Wehrens XH, Lehnart SE, Huang F, et al. FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell 2003 113 : 829 840.
40. Wehrens XH, Lehnart SE, Marks AR. Ryanodine receptor-targeted anti-arrhythmic therapy. Ann NY Acad Sci 2005 1047, 366 375.
41. Wehrens XH, Marks AR. Sudden unexplained death caused by cardiac ryanodine receptor (RyR2) mutations. Mayo Clin Proc 2004 79 (11 1365 1371.
42. Weissenburger J, Nesterenko VV, Antzelevitch C. Transmural heterogeneity of ventricular repolarization under baseline and long QT conditions in the canine heart in vivo: torsades de pointes develops with halo-thane but not pentobarbital anesthesia. J Cardiovasc Electrophysiol 2000 11 (3 290 304.
43. Wu XD, Dai DZ, Zhang GQ, Gao F. Propranolol and verapamil inhibit mRNA expression of RyR2 and SERCA in L-thyroxin-induced rat ventricular hypertrophy. Acta Pharmacol Sinica 2004 25 : 347 351.
44. Yang F, Dai DZ, An LF, Guo XF. Heart hypertrophy induced by levothyroxine aggravates ischemic lesions and reperfusion arrhythmias in rats. Acta Pharmacol Sinica 1997 18 : 71 74.
45. Yu F, Dai DZ, An LF, Guo XF. Heart hypertrophy induced by levothyroxine aggravates ischemic lesions and reperfusion arrhythmias in rats. Acta Pharmacol Sinica 1997 18 : 71 74.
46. Zhang C, Lin Y, Hua WY. Synthesis of chiral compounds of 4-chlorobenzyl tetrahydroberberine chloride. J Chin Pharmacol Univ 2004 35 : 393 396.